F4 Pharma: The EU invests in a promising new COVID-19 therapy

The COVend research project aims to deliver a new therapy against COVID-19 that prevents the severe stages of the disease

Since the beginning of the coronavirus pandemic, over 2.7 million hospitalisations of COVID-19 have occurred in Europe alone1 . About 14% of those with mild and moderate symptoms have developed severe symptoms and been eventually admitted into Intensive Care Units (ICUs)2 .

A challenge for Intensive Care Units

Unfortunately, the most common treatments for the first two stages of the illness (remdesivir and antibody therapy) have not shown the desired effect nor stopped the progression to critical stages. Adding to this, the slow progress of vaccination programmes in many European countries and the emergence of new variants, a therapeutic breakthrough is in dire need.

The COVend project

Although the COVID-19 pandemic has changed our way of living for almost two years, there is still no direct therapy currently available, but rather it is limited to symptom control. As a reaction to this, Horizon Europe has newly funded the COVend project, which aims to stop the COVID-19 progression to severe by delivering a new effective treatment option for patients suffering from the infection during mild and moderate stages. This multidisciplinary consortium unites 17 partners from 13 European countries with expertise from different disciplines, including (cell) biology, ICT expertise for AI based evaluations, pharma, economics, and social sciences, as well as clinical expertise. In addition to reducing the burden on patients, their families and the healthcare sector, COVend’s solution would help provide ICU beds for non-COVID patients requiring immediate interventions, such as heart or cancer surgeries. COVend’s mission is to achieve these results by testing the promising candidate FX06, a peptide that targets the endothelium, which is a thin membrane that lines the inside of the heart and blood vessels, and that appears to be affected by the virus. The consortium, coordinated by Prof. Kai Zacharowski, will study the influence of COVID-19 on endothelial cells and the potential protective effect of FX06, by applying OMICS technologies, generating new algorithms and opensource software for data analytics and modelling, and developing health economic models that assess the benefits and cost-effectiveness of the therapy.

The COVend Consortium

  • This multidisciplinary consortium unites 17 partners from 13 European countries:
  • Johann Wolfgang Goethe-Universität Frankfurt
  • accelopment Schweiz AG
  • European Society of Anaesthesiology and Intensive Care
  • Fraunhofer Institute for Translational Medicine and Pharmacology
  • F4-Pharma GmbH
  • Tampere University, Faculty of Medicine and Health Technology
  • University College Dublin, Systems Biology Ireland
  • University Medical Center Groningen, Department of Health Sciences
  • Medical Intelligent Data Analytics GmbH
  • University Hospital Würzburg
  • ASST Fatebenefratelli Sacco – Luigi Sacco Hospital
  • Ospedale S. Maria della Misericordia, University of Perugia
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
  • Hospital Universitari de Bellvitge
  • Carol Davila University of Medicine and Pharmacy
  • Centro Hospitalar e Universitario de Coimbra E.P.E.
  • Assistance Publique Hopitaux de Paris


Johann Wolfgang Goethe-Universität Frankfurt
Prof. Dr. Dr. Kai Zacharowski
Project Coordinator

accelopment Schweiz AG
Sara Rodriguez
Project Manager Communications
T: +41 044 455 66 00


The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.